Himadri Speciality Chemical Ltd

Himadri Speciality Chemical Ltd has announced the incorporation of its wholly-owned foreign subsidiary, ARDENT IMPEX FZCO, in Dubai, UAE. This new entity, established in the Dubai Airport Free Zone with an authorized capital of AED 200,000, will focus on Industrial Chemicals Trading and Petrochemicals Trading. The subsidiary has not yet commenced business operations. The incorporation is part of the company's strategy to expand its trading activities in the UAE market. The investment will be made in cash.

Himadri Speciality Chemical Ltd has remitted an additional AUD 16,94,000 in cash for the last tranche of investment in Sicona Battery Technologies Pty Ltd, subscribing to 16,94,000 Compulsorily Convertible Notes (CCNs). This brings the company's cumulative holding in Sicona to 1,84,47,000 CCNs. The investment is made via CCNs, and no additional voting rights or control have been acquired by Himadri Speciality Chemical at present. The CCNs are convertible into shares of Sicona as per agreed terms. This update follows a previous announcement on May 13, 2025, regarding further investment approval.

Himadri Speciality Chemical Ltd announced record-breaking financial results for the quarter ended June 30, 2026. Consolidated revenue reached ₹1,432 Cr, a 28% increase year-on-year. EBITDA stood at ₹313 Cr, up 33% YoY, with Profit After Tax (PAT) at ₹228 Cr, a 27% increase YoY. The company highlighted strong performance driven by product mix, ramp-up in speciality materials, and execution of its diversification strategy. Key growth initiatives include developing indigenous Carbon Nanotube (CNT) technology with a planned 200 MTPA facility and expanding into Super Speciality Carbon Black (SSCB). The New Energy Materials business is a focus, with advancements in anode and LFP cathode materials, targeting significant capacity expansions. Strategic investments in Sicona and IBC further bolster its position in the battery materials ecosystem.

Himadri Speciality Chemical Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, issued by ICRA Limited. The report confirms that the utilization of proceeds from the Preferential Issue of Warrants, amounting to ₹341.8172 Crores, is in line with the stated objects of the issue. There has been no deviation observed in the utilization of funds. The report is prepared as per SEBI regulations and does not constitute an audit or assurance on the quality or outcome of the spending.

Himadri Speciality Chemical Ltd announced board approval for significant capital expenditures across multiple projects. The company will invest ₹128 Crores to expand Anthraquinone and Carbazole manufacturing capacity, ₹70 Crores for India's first Carbon Nano Tubes (CNT) facility, and ₹170 Crores for Super Speciality Carbon Black production. These expansions aim to enhance production of high-value specialty products and reduce import dependency, aligning with the 'Atmanirbhar Bharat' vision. The board also approved the unaudited financial results for the quarter ended 30 June 2026.

Himadri Speciality Chemical Ltd announced board approval for significant capital expenditures. This includes an additional ₹128 Crores to expand Anthraquinone and Carbazole manufacturing capacity from 2600 MTPA to 5300 MTPA, with phased commissioning by Q2FY27 and Q2FY28. The company also approved ₹70 Crores for India's first Carbon Nano Tubes (CNT) manufacturing facility in West Bengal, with a capacity of 200 MTPA, expected by Q4FY27. Furthermore, a capex of ₹170 Crores is allocated for Super Speciality Carbon Black (SSCB) manufacturing with a capacity of 6,000 MTPA, to be commissioned by Q4FY28. These expansions are primarily funded through internal accruals and align with the company's strategy to focus on high-value products and reduce import dependency.

Himadri Speciality Chemical Ltd has announced the issuance and allotment of Commercial Paper (CP) amounting to ₹150 Crore. The Finance and Management Committee of the Board of Directors approved the allotment of 3,000 units of CP, each with a face value of ₹5,00,000/-, aggregating to ₹150 Crore. The instrument has a tenure of 90 days, with a coupon rate of 6.60% per annum, payable upfront. The CP is unsecured, will be listed on BSE Ltd, and is issued in favor of Kotak Mahindra Bank. The maturity date for this issuance is October 7, 2026.

Himadri Speciality Chemical Ltd has announced that its Board of Directors will convene on July 15, 2026. The primary agenda for this meeting is to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the quarter ending June 30, 2026. Additionally, the company has informed about the reopening of the trading window for its securities, which will be effective 48 hours after the declaration of these financial results.

Himadri Speciality Chemical Ltd announced the allotment of 19,000 equity shares of Re.1 each to eligible employees under the "Himadri Employee Stock Option Plan 2016". The exercise price per share was ₹140, with a premium of ₹139 per share. This allotment increases the company's issued and paid-up capital to ₹50,45,60,599, comprising 50,45,60,599 equity shares. The new shares rank pari-passu with existing shares. The filing also provides details as per SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021.

Mahabir Prasad Agarwal and a group of Persons Acting in Concert (PACs) have disclosed a change in their shareholding in Himadri Speciality Chemical Limited. The group has sold a net of 99,00,000 shares, reducing their total holding from 8.21% to 6.25% of the company's total share capital. The transactions occurred through open market and inter-se transfers between March 19, 2025, and July 1, 2026. The total diluted share capital of the company remains largely stable.